Table 7.
Efficacy and potency of pure cannabinoids and of most of their corresponding ‘botanical drug substance’ (BDS) as inhibitors of rat brain FAAH
| Compounds | IC50 (µM) | Maximum concentration tested (% inhibition) |
|---|---|---|
| CBC | >100 µM | 100 µM |
| 46.5 ± 1.3 | ||
| CBC-BDS | 53.2 ± 11.3 | 100 µM |
| 68.6 ± 4.1 | ||
| CBD | 15.2 ± 3.2 | 50 µM |
| 87.2 ± 4.1 | ||
| CBD-BDS | 30.8 ± 6.2 | 100 µM |
| 89.4 ± 2.5 | ||
| CBG | >100 µM | 100 µM |
| 44.9 ± 1.4 | ||
| CBG-BDS | 62.9 ± 21.4 | 100 µM |
| 66.9 ± 5.0 | ||
| CBN | >50 µM | 50 µM |
| 29.1 ± 3.3 | ||
| CBDA | >50 µM | 50 µM |
| 42.2 ± 4.0 | ||
| CBDA-BDS | >50 µM | 50 µM |
| 43.9 ± 6.0 | ||
| CBGA | >50 µM | 50 µM |
| 46.2 ± 4.9 | ||
| CBDV | >100 µM | 100 µM |
| 36.2 ± 3.1 | ||
| CBDV-BDS | 53.4 ± 8.3 | 100 µM |
| 77.9 ± 1.1 | ||
| CBGV | >50 µM | 50 µM |
| 38.7 ± 3.8 | ||
| CBGV-BDS | >50 µM | 50 µM |
| 45.3 ± 6.5 | ||
| THCA | >50 µM | 50 µM |
| 38.8 ± 3.1 | ||
| THCA-BDS | >50 µM | 50 µM |
| 44.4 ± 4.0 | ||
| THCV | >100 µM | 100 µM |
| 26.8 ± 3.4 | ||
| THCV-BDS | >100 µM | 100 µM |
| 48.3 ± 3.4 | ||
| THCVA | >100 µM | 100 µM |
| 27.0 ± 3.6 | ||
| THCVA-BDS | >50 µM | 100 µM |
| 62.1 ± 1.4 |
Data are means ± SEM of at least n = 3 separate experiments in which various concentrations (1, 10, 25, 50 or 100 µM) of the pure compounds/BDS were incubated. Efficacy was calculated as % of FAAH inhibition at the maximal concentration tested (which is shown in the first line of the cell).
CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiol acid; CBDV, propyl analogue of CBD or cannabidivarin; CBG, cannabigerol; CBGV, cannabigivarin; CBN, cannabinol; FAAH, fatty acid amide hydrolase; THC, Δ9-tetrahydrocannabinol; THCA, THC acid; THCV, propyl analogue of THC or tetrahydrocannabivarin; THCVA, tetrahydrocannabivarin acid.